No profile data available.
Taysha Gene Therapies, Inc. (TSHA) is a healthcare company in the brain and nerve treatment drugs industry, based in Dallas, United States, with about 99 full-time employees.
It reported revenue of $9.77 million for fiscal year 2025, up 17.3% from fiscal year 2024, and net income of -$109.00 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0, down 100.0% from a year before. Its market capitalization was $1.46 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
Taysha Gene Therapies reported $9.77 million in revenue for fiscal year 2025, up 17.3% from $8.33 million in fiscal year 2024. In Q2 2026 revenue was $0.
$1.46 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Compass Pathways plc (CMPS), Stoke Therapeutics, Inc. (STOK), Rapport Therapeutics, Inc. (RAPP), Mind Medicine (MindMed) Inc. (MNMD).